CURRENT TREATMENT OPTIONS FOR INVASIVE ASPERGILLOSIS

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorBATISTA, M. V.
dc.contributor.authorCOSTA, S. F.
dc.contributor.authorSHIKANAI-YASUDA, M. A.
dc.contributor.authorMOSS, R. B.
dc.date.accessioned2013-09-23T16:39:42Z
dc.date.available2013-09-23T16:39:42Z
dc.date.issued2013
dc.description.abstractInvasive pulmonary aspergillosis is a major cause of morbidity and mortality in immunocom promised patients, particularly those with hematological malignancies in the setting of profound neutropenia and/or hematopoietic stem cell transplant recipients. The optimal therapy for invasive aspergillosis relies on the restoration of leukocyte counts and effective antifungal treatment initiated at the earliest stage of infection. Several alternative antifungal compounds are currently available. A rational approach should take into account not only the degree of certainty of infection (as codified by the EORTC/MSG classification), but also previous exposure to other antifungals, the pharmacokinetic and pharmacodynamic characteristics of the antifungals employed and the clinical characteristics of the patient.
dc.description.indexMEDLINE
dc.description.sponsorshipPfizer
dc.description.sponsorshipMerck Sharp Dohme
dc.description.sponsorshipNovartis
dc.description.sponsorshipUnited Medical
dc.identifier.citationDRUGS OF TODAY, v.49, n.3, p.213-226, 2013
dc.identifier.doi10.1358/dot.2013.49.3.1921234
dc.identifier.issn1699-3993
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/1967
dc.language.isoeng
dc.publisherPROUS SCIENCE, SAU-THOMSON REUTERS
dc.relation.ispartofDrugs of Today
dc.rightsrestrictedAccess
dc.rights.holderCopyright PROUS SCIENCE, SAU-THOMSON REUTERS
dc.subjectInvasive aspergillosis
dc.subjectAntifungal therapy
dc.subjectAntifungal drugs
dc.subjectVoriconazole
dc.subjectCaspofungin
dc.subjectAmphotericin B
dc.subjectImmunocompromised hosts
dc.subjectPolyene antibiotics
dc.subjectAzoles
dc.subjectEchinocandins
dc.subjectInvasive fungal infection
dc.subject.otherliposomal amphotericin-b
dc.subject.otherempirical antifungal therapy
dc.subject.otherhematopoietic-cell transplantation
dc.subject.otherfungal-infections
dc.subject.otherimmunocompromised patients
dc.subject.othercolloidal dispersion
dc.subject.otherneutropenic patients
dc.subject.otherpersistent fever
dc.subject.otherdouble-blind
dc.subject.otherhematologic malignancies
dc.subject.wosPharmacology & Pharmacy
dc.titleCURRENT TREATMENT OPTIONS FOR INVASIVE ASPERGILLOSIS
dc.typearticle
dc.type.categoryreview
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.affiliation.countryEstados Unidos
hcfmusp.affiliation.countryisous
hcfmusp.author.externalMOSS, R. B.:Stanford Univ, Med Ctr, Ctr Excellence Pulm Biol, Dept Pediat, Palo Alto, CA 94304 USA
hcfmusp.citation.scopus6
hcfmusp.contributor.author-fmusphcMARJORIE VIEIRA BATISTA
hcfmusp.contributor.author-fmusphcSILVIA FIGUEIREDO COSTA
hcfmusp.contributor.author-fmusphcMARIA APARECIDA SHIKANAI YASUDA
hcfmusp.description.beginpage213
hcfmusp.description.endpage226
hcfmusp.description.issue3
hcfmusp.description.volume49
hcfmusp.origemWOS
hcfmusp.origem.pubmed23527325
hcfmusp.origem.scopus2-s2.0-84875756916
hcfmusp.origem.wosWOS:000316918900006
hcfmusp.publisher.cityBARCELONA
hcfmusp.publisher.countrySPAIN
hcfmusp.relation.referenceAuberger J, 2012, J ANTIMICROB CHEMOTH, V67, P2268, DOI 10.1093/jac/dks189
hcfmusp.relation.referenceBergeron A, 2012, J CLIN MICROBIOL, V50, P823, DOI 10.1128/JCM.00750-11
hcfmusp.relation.referenceBlot F, 2002, NEW ENGL J MED, V347, P2080
hcfmusp.relation.referenceBohme A, 2009, ANN HEMATOL, V88, pCP6, DOI 10.1007/s00277-008-0622-5
hcfmusp.relation.referenceBowden R, 2002, CLIN INFECT DIS, V35, P359, DOI 10.1086/341401
hcfmusp.relation.referenceCaillot D, 2003, ACTA HAEMATOL-BASEL, V109, P111, DOI 10.1159/000069281
hcfmusp.relation.referenceCaillot D, 2007, CANCER, V110, P2740, DOI 10.1002/cncr.23109
hcfmusp.relation.referenceCappelletty D, 2007, PHARMACOTHERAPY, V27, P369, DOI 10.1592/phco.27.3.369
hcfmusp.relation.referenceCornely OA, 2007, NEW ENGL J MED, V356, P348, DOI 10.1056/NEJMoa061094
hcfmusp.relation.referenceCornely OA, 2007, CLIN INFECT DIS, V44, P1289, DOI 10.1086/514341
hcfmusp.relation.referenceDENNING DW, 1994, AM J MED, V97, P135, DOI 10.1016/0002-9343(94)90023-X
hcfmusp.relation.referenceDenning DW, 2006, J INFECTION, V53, P337, DOI 10.1016/j.jinf.2006.03.003
hcfmusp.relation.referenceDe Pauw B, 2008, CLIN INFECT DIS, V46, P1813, DOI 10.1086/588660
hcfmusp.relation.referenceDiaz-Guerra TM, 2003, ANTIMICROB AGENTS CH, V47, P1120, DOI 10.1128/AAC.47.3.1120-1124.2003
hcfmusp.relation.referenceDouglas CM, 2001, MED MYCOL, V39, P55, DOI 10.1080/744118880
hcfmusp.relation.referenceEllis M, 1998, CLIN INFECT DIS, V27, P1406, DOI 10.1086/515033
hcfmusp.relation.referenceFeola D, 1997, CLIN INFECT DIS, V25, P344
hcfmusp.relation.referenceGOODMAN JL, 1992, NEW ENGL J MED, V326, P845, DOI 10.1056/NEJM199203263261301
hcfmusp.relation.referenceGraf K, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-163
hcfmusp.relation.referenceHerbrecht R, 2002, NEW ENGL J MED, V347, P408, DOI 10.1056/NEJMoa020191
hcfmusp.relation.referenceHoward SJ, 2009, EMERG INFECT DIS, V15, P1068, DOI 10.3201/eid1507.090043
hcfmusp.relation.referenceIde L, 2004, CLIN MICROBIOL INFEC, V10, P862, DOI 10.1111/j.1469-0691.2004.00945.x
hcfmusp.relation.referenceJantunen E, 1997, BONE MARROW TRANSPL, V19, P801, DOI 10.1038/sj.bmt.1700737
hcfmusp.relation.referenceJohnson JR, 2002, NEW ENGL J MED, V346, P1745, DOI 10.1056/NEJM200205303462213
hcfmusp.relation.referenceKarthaus M, 2002, NEW ENGL J MED, V347, P2080
hcfmusp.relation.referenceKontoyiannis DP, 2005, CANCER, V103, P2334, DOI 10.1002/cncr.21057
hcfmusp.relation.referenceKontoyiannis DP, 2005, NEW ENGL J MED, V352, P410
hcfmusp.relation.referenceKontoyiannis DP, 2010, CLIN INFECT DIS, V50, P1091, DOI 10.1086/651263
hcfmusp.relation.referenceLeeflang MM, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007394
hcfmusp.relation.referenceLellek H, 2011, MYCOSES, V54, P39, DOI 10.1111/j.1439-0507.2010.01985.x
hcfmusp.relation.referenceLin SJ, 2001, CLIN INFECT DIS, V32, P358, DOI 10.1086/318483
hcfmusp.relation.referenceLockhart S.R., 2012, ANTIMICROB AGENTS CH, V55, P4465
hcfmusp.relation.referenceMaertens J, 2011, BONE MARROW TRANSPL, V46, P709, DOI 10.1038/bmt.2010.175
hcfmusp.relation.referenceMaertens J, 2004, CLIN INFECT DIS, V39, P1563, DOI 10.1086/423381
hcfmusp.relation.referenceMarr KA, 2000, BLOOD, V96, P2055
hcfmusp.relation.referenceMarr KA, 2004, BLOOD, V103, P1527, DOI 10.1182/blood-2003-08-2644
hcfmusp.relation.referenceMarr KA, 2002, NEW ENGL J MED, V346, P278, DOI 10.1056/NEJM200201243460410
hcfmusp.relation.referenceMarr KA, 2002, CLIN INFECT DIS, V34, P909, DOI 10.1086/339202
hcfmusp.relation.referenceMarr KA, 2004, CLIN INFECT DIS, V39, P797, DOI 10.1086/423380
hcfmusp.relation.referenceMasia CM, 2002, LANCET INFECT DIS, V2, P550
hcfmusp.relation.referenceMehta J, 1997, BONE MARROW TRANSPL, V20, P39, DOI 10.1038/sj.bmt.1700842
hcfmusp.relation.referenceMellinghoff IK, 2002, CLIN INFECT DIS, V34, P1648, DOI 10.1086/340522
hcfmusp.relation.referenceMetan G, 2013, MYCOSES, V56, P34, DOI 10.1111/j.1439-0507.2012.02195.x
hcfmusp.relation.referenceMihu CN, 2010, CANCER-AM CANCER SOC, V116, P5290, DOI 10.1002/cncr.25312
hcfmusp.relation.referenceMILLS W, 1994, BRIT J HAEMATOL, V86, P754, DOI 10.1111/j.1365-2141.1994.tb04825.x
hcfmusp.relation.referenceMortensen KL, 2011, EUR J CLIN MICROBIOL, V30, P1355, DOI 10.1007/s10096-011-1229-7
hcfmusp.relation.referenceNG TTC, 1995, ARCH INTERN MED, V155, P1093, DOI 10.1001/archinte.155.10.1093
hcfmusp.relation.referenceOPPENHEIM BA, 1995, CLIN INFECT DIS, V21, P1145, DOI 10.1093/clinids/21.5.1145
hcfmusp.relation.referencePascual A, 2008, CLIN INFECT DIS, V46, P201, DOI 10.1086/524669
hcfmusp.relation.referencePerfect JR, 2003, CLIN INFECT DIS, V36, P1122, DOI 10.1086/374557
hcfmusp.relation.referencePERFECT JR, 1992, J INFECT DIS, V165, P891
hcfmusp.relation.referencePERSAT F, 1992, EUR J CANCER, V28A, P838, DOI 10.1016/0959-8049(92)90127-N
hcfmusp.relation.referencePitisuttithum P, 2005, J ANTIMICROB CHEMOTH, V56, P745, DOI 10.1093/jac/dki288
hcfmusp.relation.referencePopp A I, 1999, Int J Infect Dis, V3, P157, DOI 10.1016/S1201-9712(99)90038-3
hcfmusp.relation.referencePowers JH, 2002, NEW ENGL J MED, V346, P289, DOI 10.1056/NEJM200201243460414
hcfmusp.relation.referencePrentice AG, 2005, J ANTIMICROB CHEMOTH, V56, P17
hcfmusp.relation.referencePrentice HG, 1997, BRIT J HAEMATOL, V98, P711, DOI 10.1046/j.1365-2141.1997.2473063.x
hcfmusp.relation.referencePurkins L, 2002, ANTIMICROB AGENTS CH, V46, P2546, DOI 10.1128/AAC.46.8.2546-2553.2002
hcfmusp.relation.referenceRaad II, 2008, LEUKEMIA, V22, P496, DOI 10.1038/sj.leu.2405065
hcfmusp.relation.referenceRINGDEN O, 1991, J ANTIMICROB CHEMOTH, V28, P73
hcfmusp.relation.referenceSingh N, 2006, TRANSPLANTATION, V81, P320, DOI 10.1097/01.tp.0000202421.94822.f7
hcfmusp.relation.referenceSkiada A, 2011, CLIN MICROBIOL INFEC, V17, P1859, DOI 10.1111/j.1469-0691.2010.03456.x
hcfmusp.relation.referenceSLAVIN MA, 1995, J INFECT DIS, V171, P1545
hcfmusp.relation.referenceSteinbach WJ, 2003, CLIN INFECT DIS, V37, pS188, DOI 10.1086/376524
hcfmusp.relation.referenceSteinbach WJ, 2012, J INFECTION, V65, P453, DOI 10.1016/j.jinf.2012.08.003
hcfmusp.relation.referenceStone JA, 2002, ANTIMICROB AGENTS CH, V46, P739, DOI 10.1128/AAC.46.3.739-745.2002
hcfmusp.relation.referenceTashiro M, 2012, ANTIMICROB AGENTS CH, V56, P584, DOI 10.1128/AAC.05394-11
hcfmusp.relation.referenceTheel ES, 2013, MYCOPATHOLOGIA, V175, P33, DOI 10.1007/s11046-012-9579-y
hcfmusp.relation.referenceTheuretzbacher U, 2006, CLIN PHARMACOKINET, V45, P649, DOI 10.2165/00003088-200645070-00002
hcfmusp.relation.referenceTOLLEMAR J, 1992, DRUG INVEST, V4, P232
hcfmusp.relation.referenceUllmann AJ, 2007, NEW ENGL J MED, V356, P335, DOI 10.1056/NEJMoa061098
hcfmusp.relation.referenceUppin MS, 2011, INDIAN J PATHOL MICR, V54, P344, DOI 10.4103/0377-4929.81634
hcfmusp.relation.referenceUpton A, 2007, CLIN INFECT DIS, V44, P531, DOI 10.1086/510592
hcfmusp.relation.referencevan Burik JAH, 2004, CLIN INFECT DIS, V39, P1407, DOI 10.1086/422312
hcfmusp.relation.referencevan der Linden JWM, 2011, EMERG INFECT DIS, V17, P1846, DOI 10.3201/eid1710.110226
hcfmusp.relation.referenceVerweij Paul E, 2012, Ned Tijdschr Geneeskd, V156, pA4458
hcfmusp.relation.referenceWalsh TJ, 2002, NEW ENGL J MED, V346, P225, DOI 10.1056/NEJM200201243460403
hcfmusp.relation.referenceWalsh TJ, 2008, CLIN INFECT DIS, V46, P327, DOI 10.1086/525258
hcfmusp.relation.referenceWalsh TJ, 1999, NEW ENGL J MED, V340, P764, DOI 10.1056/NEJM199903113401004
hcfmusp.relation.referenceWalsh TJ, 2004, NEW ENGL J MED, V351, P1391, DOI 10.1056/NEJMoa040446
hcfmusp.relation.referenceWalsh TJ, 1998, CLIN INFECT DIS, V26, P1383, DOI 10.1086/516353
hcfmusp.relation.referenceWhite MH, 1998, CLIN INFECT DIS, V27, P296, DOI 10.1086/514672
hcfmusp.relation.referenceWhite MH, 1997, CLIN INFECT DIS, V24, P635
hcfmusp.relation.referenceWingard JR, 2010, BLOOD, V116, P5111, DOI 10.1182/blood-2010-02-268151
hcfmusp.remissive.sponsorshipMerck
hcfmusp.remissive.sponsorshipNovartis
hcfmusp.remissive.sponsorshipPfizer
hcfmusp.scopus.lastupdate2024-05-17
relation.isAuthorOfPublication65fef186-1289-4bf2-8c60-34bd10156450
relation.isAuthorOfPublicationd786dd7f-b93c-49e1-8561-c635a58c378f
relation.isAuthorOfPublication6d14d2a4-653a-4769-8c38-5a594ab3a09f
relation.isAuthorOfPublication.latestForDiscovery65fef186-1289-4bf2-8c60-34bd10156450
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
art_BATISTA_CURRENT_TREATMENT_OPTIONS_FOR_INVASIVE_ASPERGILLOSIS_2013.PDF
Tamanho:
231.32 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MIP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/48
Artigos e Materiais de Revistas Científicas - LIM/54